is retatrutide approved in other countries Retatrutide, an experimental weight-loss drug, has not been by the FDA. But, doctors and nurse practitioners clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

10.1111/adb.12953 75 VestlundJ.JerlhagE

GIP works synergistically with GLP-1 to enhance insulin secretion and appears to have metabolic effects that support weight loss

doi: 10.1016/S2213-8587(19)30249-9 [DOI] [PubMed] [Google Scholar] 36.Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E

Other drugs in development Other multiagonists based on GLP-1 in combination with peptides such as GIP, GCG, PYY, secretin, and GLP-2as well as new triagonists and tetraagonists incorporating DACRA agonismare currently in the early stages of development1,59 (Table 2)

Retatrutide's GLP-1 affinity is the floor of the stack most of the early appetite suppression in the first 4-8 weeks is reportedly GLP-1-mediated